Fulgent Genetics Reports Fourth Quarter and Full Year 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Fulgent Genetics, Inc. (FLGT) Tops Q4 EPS by 87c; Guides
February 23, 2022 4:18 PM ESTFulgent Genetics, Inc. (NASDAQ: FLGT) reported Q4 EPS of $3.48, $0.87 better than the analyst estimate of $2.61. Revenue for the quarter came in at $251.7 million versus the consensus estimate of $191.1 million.
GUIDANCE:
Fulgent Genetics, Inc. sees Q1 2022 revenue of ~$245 million, versus the... More
